Financial Contrast: Biosig Technologies (STEX) vs. The Competition

Biosig Technologies (NASDAQ:STEX) is one of 28 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it contrast to its rivals? We will compare Biosig Technologies to similar businesses based on the strength of its analyst recommendations, earnings, valuation, dividends, profitability, institutional ownership and risk.

Institutional & Insider Ownership

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Biosig Technologies and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Biosig Technologies	$40,000.00	-$10.33 million	-1.79
Biosig Technologies Competitors	$59.55 million	-$32.15 million	4.18

Biosig Technologies’ rivals have higher revenue, but lower earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations and price targets for Biosig Technologies and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1	0	0	0	1.00
Biosig Technologies Competitors	77	76	156	6	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 51.09%. Given Biosig Technologies’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Biosig Technologies has less favorable growth aspects than its rivals.

Profitability

This table compares Biosig Technologies and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	N/A	-64.96%
Biosig Technologies Competitors	-672.41%	-133.75%	-59.01%

Risk & Volatility

Biosig Technologies has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Biosig Technologies’ rivals have a beta of 1.76, meaning that their average share price is 76% more volatile than the S&P 500.

Summary

Biosig Technologies rivals beat Biosig Technologies on 9 of the 13 factors compared.

Biosig Technologies Company Profile

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.